Regulatory Setback For Applied Therapeutics' Lead Program, FDA Highlights Deficiencies In Clinical Application
Benzinga · 598 days
High Materiality8/10
AI Summary
FDA issued a Complete Response Letter for APLT's govorestat NDA. Deficiencies in clinical application cited, delaying potential approval and launch. William Blair downgraded success probability for galactosemia to 30%. SORD program remains unaffected; potential revenue by late 2025 possible. APLT stock dropped 67.2% following the FDA's decision.
Sentiment Rationale
The CRL significantly impairs approval timeline, similar past reactions saw deeper declines.
Trading Thesis
Approval delays may affect long-term revenue projections, akin to other biotech cases.
Market-Moving
- FDA issued a Complete Response Letter for APLT's govorestat NDA.
- Deficiencies in clinical application cited, delaying potential approval and launch.
- William Blair downgraded success probability for galactosemia to 30%.
Key Facts
- FDA issued a Complete Response Letter for APLT's govorestat NDA.
- Deficiencies in clinical application cited, delaying potential approval and launch.
- William Blair downgraded success probability for galactosemia to 30%.
- SORD program remains unaffected; potential revenue by late 2025 possible.
- APLT stock dropped 67.2% following the FDA's decision.
Companies Mentioned
- SORD (SORD)
Others
Article outlines a critical setback which directly impacts APLT's viability and investor perception.